At EVolution Therapeutics, our science centres on one principle: healing happens when the body actively resolves inflammation. The immune system does more than defend against injury and infection. It also controls the switch that turns inflammation off and starts tissue repair. However, in many chronic diseases, this resolution phase fails. Immune cells stay locked in a pro-inflammatory state. As a result, regeneration stalls and tissues remain trapped in a cycle of damage.
Therefore, we focus on reprogramming this process. Using advanced lipid nanoparticle (LNP) technology, we deliver targeted molecular signals directly to the wound environment. These RNA-loaded nanoparticles are released in a controlled manner from a biodegradable hydrogel, enabling localised and sustained delivery at the site of injury. As the hydrogel gradually degrades, it supports continued exposure to therapeutic signals while avoiding systemic suppression.
These signals actively modulate immune behaviour and drive the shift from inflammation to resolution. Instead of suppressing the immune system, we restore its natural healing function. In doing so, we promote pro-resolving immune activity, support angiogenesis, and restart tissue repair. By acting at the level of immune regulation, we address a core mechanism shared across inflammatory disease.
Initially, we are applying this approach to chronic wound healing, with a focus on diabetic foot ulcers where inflammation fails to resolve. Here, our locally delivered nanoparticle therapy intervenes at a critical bottleneck. It resets the wound environment and enables functional healing to begin again.
So far, preclinical studies show strong promise. Our platform modulates inflammatory responses and accelerates wound closure in both cellular and animal models. By combining immune modulation with controlled hydrogel release, we move beyond passive care. Instead, we actively guide the immune system toward resolution, regeneration, and sustained repair where it is needed most.